[go: up one dir, main page]

MX2019006299A - Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas. - Google Patents

Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.

Info

Publication number
MX2019006299A
MX2019006299A MX2019006299A MX2019006299A MX2019006299A MX 2019006299 A MX2019006299 A MX 2019006299A MX 2019006299 A MX2019006299 A MX 2019006299A MX 2019006299 A MX2019006299 A MX 2019006299A MX 2019006299 A MX2019006299 A MX 2019006299A
Authority
MX
Mexico
Prior art keywords
compounds
methods
pirazola
substitute
treatment
Prior art date
Application number
MX2019006299A
Other languages
English (en)
Inventor
Ciblat Stephane
Dery Martin
Grand-Maitre Chantal
W Shipps Gerald
Bruneau-Latour Nicolas
M Siddiqui Arshad
CONSTANTINEUA-FORGET Lea
B Cooper Alan
Oza Vibha
W Kostura Matthew
Luther Michael
Levine Jedd
Original Assignee
Bantam Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical Llc filed Critical Bantam Pharmaceutical Llc
Publication of MX2019006299A publication Critical patent/MX2019006299A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos útiles, por ejemplo, en métodos para tratar trastornos hiperproliferativos, tales como cáncer, métodos para detener el ciclo celular en células cancerosas, métodos para inhibir la síntesis de glutatión en células cancerosas, y compuestos asociados para usar, así como usos en medicamentos; en ciertas formas de realización, los métodos, usos y compuestos se proporcionan en referencia a compuestos de las fórmulas estructurales (Ia), (Ib), (Ic), (Id) y (Ie),(ver formula) en donde R1, L1, L2, Q, L3, R3, L4, R4, L5, y R5 son como se describen en la presente; en ciertas formas de realización, los compuestos descritos en la presente son especialmente activos contra tipos de cáncer que tienen un gen KRAS mutante.
MX2019006299A 2016-11-30 2017-11-29 Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas. MX2019006299A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662428271P 2016-11-30 2016-11-30
PCT/US2017/063774 WO2018102453A1 (en) 2016-11-30 2017-11-29 Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Publications (1)

Publication Number Publication Date
MX2019006299A true MX2019006299A (es) 2019-11-12

Family

ID=62241871

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006299A MX2019006299A (es) 2016-11-30 2017-11-29 Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.

Country Status (11)

Country Link
US (2) US11325903B2 (es)
EP (1) EP3548482A4 (es)
JP (1) JP7373992B2 (es)
CN (2) CN118930533A (es)
AU (1) AU2017366901B2 (es)
BR (1) BR112019011044A2 (es)
CA (1) CA3081983A1 (es)
IL (1) IL266930B2 (es)
MX (1) MX2019006299A (es)
NZ (1) NZ754827A (es)
WO (1) WO2018102453A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
MX2019006296A (es) * 2016-11-30 2019-11-12 Bantam Pharmaceutical Llc Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas.
NZ754827A (en) * 2016-11-30 2025-10-31 Bantam Pharmaceutical Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
IL274601B2 (en) 2017-11-15 2024-04-01 Mirati Therapeutics Inc Kras g12c inhibitors
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2021527059A (ja) 2018-06-07 2021-10-11 バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ 置換ピロール及びピラゾール化合物による癌の治療方法、並びに、置換ピロール及びピラゾール化合物による治療に影響を受けやすい癌の診断
EP3849536A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
CA3111977A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
SG11202102377YA (en) 2018-09-10 2021-04-29 Mirati Therapeutics Inc Combination therapies
EP3890716A4 (en) 2018-12-05 2022-12-21 Mirati Therapeutics, Inc. COMBINATION THERAPIES
JP7592601B2 (ja) 2019-01-10 2024-12-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
EP3976606A1 (en) * 2019-05-31 2022-04-06 Bantam Pharmaceutical, LLC Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative
EP3976605B1 (en) * 2019-05-31 2025-08-20 Bantam Pharmaceutical, LLC Methods for making thiazolylpyrazole carboxylic acids and intermediates therefor
PH12022550469A1 (en) 2019-08-29 2023-02-27 Array Biopharma Inc Kras g12d inhibitors
EP4034123A4 (en) 2019-09-24 2023-11-01 Mirati Therapeutics, Inc. COMBINATION THERAPIES
KR20220130126A (ko) 2019-12-20 2022-09-26 미라티 테라퓨틱스, 인크. Sos1 억제제
AU2021285032A1 (en) * 2020-06-02 2022-12-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
KR20230137286A (ko) 2020-09-11 2023-10-04 미라티 테라퓨틱스, 인크. Kras g12c 억제제의 결정 형태
MX2023007084A (es) 2020-12-15 2023-08-30 Mirati Therapeutics Inc Inhibidores de pan-kras de azaquinazolina.
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
PE20241356A1 (es) 2021-12-01 2024-07-03 Boehringer Ingelheim Int Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer
JP2024543976A (ja) * 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体
CN116678810A (zh) * 2022-02-23 2023-09-01 武汉市鼎华双雄生物科技有限责任公司 细胞增殖免疫荧光检测试剂盒及其应用
CN117003651B (zh) * 2023-09-28 2024-01-02 广东嘉博制药有限公司 一种l-肾上腺素的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1301968B1 (it) 1998-07-30 2000-07-20 Zambon Spa Derivati di eritromicina ad attivita' antibiotica
PT1104759E (pt) 1999-12-03 2004-01-30 Pfizer Prod Inc Compostos heteroaril-fenil-pirazole como agentes anti-inflamatorios e analgesicos
WO2003084544A2 (en) 2002-04-04 2003-10-16 Cv Therapeutics, Inc. Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
EP1613614A2 (en) 2003-04-03 2006-01-11 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CN1805945A (zh) 2003-04-18 2006-07-19 麦克公司 作为钠通道阻滞剂的联芳基取代的噻唑、噁唑和咪唑
WO2007138110A2 (en) 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
US8642597B2 (en) 2007-08-27 2014-02-04 Basf Se Pyrazole compounds for controlling invertebrate pests
EP2264017A4 (en) 2008-04-04 2011-07-27 Takeda Pharmaceutical Heterocyclic derivative and its use
NZ588462A (en) 2008-04-28 2012-07-27 Kyorin Seiyaku Kk Cyclopentylacrylic acid amide derivative
EP2909203A4 (en) 2012-10-22 2016-04-06 Egenix Inc COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OR DISEASES RELATED TO EIF4E MALFUNCTION
US9926319B2 (en) * 2014-03-27 2018-03-27 Merck Patent Gmbh Pyridyl piperidines
EP3656770A3 (en) 2015-04-24 2020-09-09 Syngenta Participations AG Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocycles
US10537558B2 (en) * 2015-06-01 2020-01-21 Bantam Pharmaceutical, Llc Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto
MX2019006296A (es) 2016-11-30 2019-11-12 Bantam Pharmaceutical Llc Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas.
NZ754827A (en) * 2016-11-30 2025-10-31 Bantam Pharmaceutical Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
EP3976606A1 (en) * 2019-05-31 2022-04-06 Bantam Pharmaceutical, LLC Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Also Published As

Publication number Publication date
JP7373992B2 (ja) 2023-11-06
EP3548482A1 (en) 2019-10-09
AU2017366901B2 (en) 2022-09-29
US20230076820A1 (en) 2023-03-09
JP2019536785A (ja) 2019-12-19
CN110603254B (zh) 2024-04-12
RU2019120233A (ru) 2021-01-11
WO2018102453A1 (en) 2018-06-07
IL266930A (en) 2019-07-31
CN118930533A (zh) 2024-11-12
NZ754827A (en) 2025-10-31
CN110603254A (zh) 2019-12-20
AU2017366901A1 (en) 2019-07-11
US11325903B2 (en) 2022-05-10
EP3548482A4 (en) 2020-08-19
RU2019120233A3 (es) 2021-03-11
BR112019011044A2 (pt) 2019-10-08
US20190345152A1 (en) 2019-11-14
IL266930B1 (en) 2025-05-01
CA3081983A1 (en) 2018-06-07
IL266930B2 (en) 2025-09-01

Similar Documents

Publication Publication Date Title
MX2019006299A (es) Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.
ECSP19011216A (es) Inhibidores de piridopyrimdinona cdk2/4/6
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
MX2015005963A (es) Inhibidores heterociclicos de glutaminasa.
MX2019006296A (es) Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas.
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
PE20151495A1 (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
ECSP13012448A (es) Nuevas aminopirazoloquinazolinas.
NI201400102A (es) Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
MX2016007258A (es) Profarmacos de amidas de piridona utiles como moduladores de canales de sodio.
CR20110610A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
EA201791094A1 (ru) Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки
PE20151064A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen
MD20160136A2 (ro) Compuşi dihidroizochinolinonici substituiţi
UY33883A (es) Novedosos derivados heterocíclicos
CL2017003067A1 (es) Piridinas sustituidas y método de uso
UY35012A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
DOP2013000304A (es) Moduladores alostéricos positivos del receptor de acetilcolina nicotínico